Replies to post #13896 on Momenta Pharmaceuticals, Inc. (MNTA)

[MTB]

Just to be clear, I didn't say that no one else would be approved -- just not the Natco/ Mylan product referenced in the FDA response as 'clearly distinguishable from Copaxone.'

That said, I'm not aware of any others as far along as Mylan presents themselves to be, so de facto, no one else in the near or intermediate term would appear at all likely to be approved.

The genius of MNTB is their science. That's what I've been holding on for. As to the less than stellar fiscal judgment of the management, I share your opinion.

MTB

[marthambles]

As a very long term holder, I have to wonder whether it isn't time to cash in the chips. At this point, the potential for good news seems modest (possibly a partnership for FOB compounds, otherwise nothing probably until 2016). The big negative would be approval of a another copaxone generic.

While it seems unlikely, I remember how surprised many were when Amphastar's Lovenox was approved, and how ultimately it devastated the stock price.

How much more upside can their really be in the near future?